Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Brain Tumor, Cervical Cancer
Interventions: 18F-FTX; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia, ESRD
Interventions: ferric citrate; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 33
States / cities: Los Angeles, California • Aurora, Colorado • Westminster, Colorado + 26 more

Conditions: Type 2 Diabetes
Interventions: Practice Facilitation; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 2,493 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fabry Disease
Interventions: PRX-102 (pegunigalsidase alfa), agalsidase beta; Biological
Lead sponsor: Protalix; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more

Conditions: Idiopathic Hypercalciuria, Hypokalemia Caused by Thiazide Diuretics
Interventions: Spironolactone; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: Implementation of Proactive Diabetes Eye Care Program; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 3
States / cities: West Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions: CB-839, Talazoparib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more

Conditions: Diabetes Mellitus, With Complications
Interventions: Intravenous Insulin on cardiac disease in diabetic pts; Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hypertension, High Blood Pressure, Diabetes, Chronic Kidney Diseases
Interventions: LINKED-HEARTS Program; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Denton, Maryland

Conditions: Diabetes Mellitus, With Complications
Interventions: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog); Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Infections Joint Prosthetic, Overweight or Obesity, MSSA Colonization, MRSA, Chronic Kidney Diseases, Diabetes, Autoimmune Diseases, Inflammatory Disease, Tobacco Use
Interventions: Cephalexin, Doxycycline, Cefadroxil; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4,618 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 2
States / cities: Iowa City, Iowa • Rochester, Minnesota

Conditions: Gestational Diabetes Mellitus
Interventions: Food is Medicine (FIM) Intervention, Standard of Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Polycystic Ovary Syndrome, Obesity, Hyperandrogenism
Interventions: Dexamethasone, rhCG; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 7 Years to 18 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Ovarian Cancer
Interventions: Hyperpolarized 13-C-pyruvate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Months and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Foot Ulcer, Diabetic, Diabetic Foot
Interventions: NorLeu3-A(1-7) in a gel formulation; Drug
Lead sponsor: US Biotest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 12
States / cities: Tucson, Arizona • Castro Valley, California • San Diego, California + 8 more

Conditions: Short Bowel Syndrome (SBS)
Interventions: Glepaglutide 10 mg; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more

Conditions: Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions: ACTHAR Gel (adrenocorticotropic hormone); Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Albany, New York

Conditions: Cancer
Interventions: caspofungin acetate, liposomal amphotericin B; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
Interventions: BMN 255, Placebo; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Birmingham, Alabama • Chula Vista, California • Chula Vista Isles, Florida + 4 more

Conditions: Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
Interventions: paricalcitol, placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Boston, Massachusetts • Reno, Nevada + 4 more

Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions: Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements; Drug
Lead sponsor: University of Washington; Other
Eligibility: Up to 3 Days
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR

A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis

Improving Risk Factors for Diabetes Complications in Primary Care

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

Study to Evaluate the Effectiveness of a Program Developed to Improve Eye Care for Veterans With Diabetes

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities

Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Antibiotic Prophylaxis in High-Risk Arthroplasty Patients

Produce Rx in High Risk Pregnant Mothers at Harris Health

Ovarian Contribution to Androgen Production in Adolescent Girls

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants